ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2026
Prognostic significance of dynamic emotional distress during neoadjuvant therapy and surgery for resectable non-small cell lung cancer.
Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionEmotional distress (ED) is common in patients with non-small cell lung cancer (NSCLC), but the association between longitudinal ED patterns and survival during multimodality treatment remains unclear. We evaluated this association in patients with resectable NSCLC treated with neoadjuvant therapy and surgery.
methodsThis multicenter retrospective study included 167 patients with pretreatment clinical stage IB-IIIB NSCLC who underwent neoadjuvant therapy and curative-intent resection between 2018 and 2022. ED was assessed before neoadjuvant therapy, before surgery, and three months postoperatively using HADS-A, HADS-D, GAD-7, and PHQ-9. For the primary analyses, positivity on any measure indicated ED positivity. Patients were classified as persistently negative (ED0), intermittently positive (ED1), or persistently positive (ED2). Survival was evaluated using Kaplan-Meier analysis and Cox regression.
resultsOf the 167 patients, 47.3% were classified as ED0, 29.9% as ED1, and 22.8% as ED2. Median follow-up was 46 months. Three-year overall survival (OS) rates were 89.9%, 71.9%, and 57.9%, respectively (overall log-rank P < 0.001). In multivariable analyses, ED2 was associated with poorer OS (HR 5.04, 95% CI 2.55-9.99) and progression-free survival (PFS; HR 3.26, 95% CI 1.87-5.69) relative to ED0. Models combining ED and clinicopathologic variables had AUCs of 0.86 for OS and 0.80 for PFS.
conclusionsPersistent ED was associated with poorer OS and PFS. Longitudinal ED assessment may help identify supportive care needs, but its added prognostic value requires further validation.
Indexed as
Identifiers
42803834What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.